<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="832">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04334382</url>
  </required_header>
  <id_info>
    <org_study_id>1051360</org_study_id>
    <nct_id>NCT04334382</nct_id>
  </id_info>
  <brief_title>Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19</brief_title>
  <acronym>HyAzOUT</acronym>
  <official_title>Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19 (HyAzOUT): A Prospective Pragmatic Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intermountain Health Care, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Utah Department of Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Intermountain Health Care, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare two drugs (hydroxychloroquine and azithromycin) to see if
      hydroxychloroquine is better than azithromycin in treating outpatients with suspected or
      confirmed COVID-19.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hospitalization within 14 days of enrollment</measure>
    <time_frame>From enrollment to 14 days after enrollment</time_frame>
    <description>Admitted to a hospital (not merely kept for emergency room observation)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of COVID-19-attributable symptoms</measure>
    <time_frame>From enrollment to 14 days after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital-free days at 28 days</measure>
    <time_frame>Admission (day 1) to 28 days after admission (day 28)</time_frame>
    <description>Hospital-free days at 28 days (number of days patient not in hospital); calculated as worst-rank ordinal with mortality by day 28 assigned the worst score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator-free days at 28 days</measure>
    <time_frame>Admission (day 1) to 28 days after admission (day 28)</time_frame>
    <description>Ventilator-free days at 28 days (number of days patient not on a ventilator); calculated as worst-rank ordinal with mortality by day 28 assigned the worst score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU-free days at 28 days</measure>
    <time_frame>Admission (day 1) to 28 days after admission (day 28)</time_frame>
    <description>ICU-free days at 28 days, calculated as worst-rank ordinal with mortality by day 28 assigned the worst score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1550</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Hydroxychloroquine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Azithromycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>Patients in the hydroxychloroquine arm will receive hydroxychloroquine 400mg po BID x 1 day, then 200mg po BID x 4 days (dose reductions for weight &lt; 45kg). The drug dose (2.4 gm over 5 days) chosen falls at the lower end of doses proposed in various international trials, but it has proven in vitro efficacy, with a ratio of lung tissue trough concentrations to the EC50 (effective concentration to suppress 50% of viral activity) of &gt;20.</description>
    <arm_group_label>Hydroxychloroquine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>Patients in the azithromycin arm will receive azithromycin 500mg PO on day 1 plus 250mg PO daily on days 2-5.</description>
    <arm_group_label>Azithromycin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult, Age&gt;44 years, competent to provide consent

          -  Confirmed COVID-19, via a positive nucleic acid assay for COVID-19 within the last 7
             days

        Exclusion Criteria:

          -  Participants already prescribed chloroquine, hydroxychloroquine, or azithromycin

          -  Allergy to hydroxychloroquine or azithromycin

          -  History of bone marrow transplant

          -  Known G6PD (Glucose-6-Phosphate Dehydrogenase Deficiency) deficiency

          -  Chronic hemodialysis, peritoneal dialysis, continuous renal replacement therapy or
             Glomerular Filtration Rate &lt; 20ml/min/1.73m2

          -  Liver disease (e.g. Child Pugh score â‰¥ B or AST (Aspartate Transaminase)&gt;2 times upper
             limit)

          -  Psoriasis

          -  Porphyria

          -  Known cardiac conduction delay (QTc &gt; 500mSec) or taking any prescription medications
             known to prolong QT interval

          -  Concomitant use of digitalis, flecainide, amiodarone, procainamide, or propafenone

          -  Prisoner

          -  Weight &lt; 35kg

          -  Inability to follow-up - no cell phone or no address or not Spanish or English
             speaking

          -  Receipt of any experimental treatment for SARS-CoV-2 (off-label, compassionate use, or
             trial related) within the 30 days prior to the time of the screening evaluation

          -  No symptoms attributable to COVID-19

          -  Pregnant or nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brandon Webb, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Intermountain Health Care, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Valerie T Aston, MBA</last_name>
    <phone>8015074606</phone>
    <email>Valerie.Aston@imail.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David P Tomer, MS</last_name>
    <phone>801-507-4694</phone>
    <email>David.Tomer@imail.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Intermountain Medical Center</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie T Aston, MBA</last_name>
      <phone>801-507-4606</phone>
      <email>Valerie.Aston@imail.org</email>
    </contact>
    <contact_backup>
      <last_name>Jake Krong</last_name>
      <phone>801-507-9333</phone>
      <email>Jake.Krong@imail.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Estelle Harris, MD</last_name>
      <phone>801-581-7806</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 2, 2020</study_first_submitted>
  <study_first_submitted_qc>April 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2020</study_first_posted>
  <last_update_submitted>April 7, 2020</last_update_submitted>
  <last_update_submitted_qc>April 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Intermountain Health Care, Inc.</investigator_affiliation>
    <investigator_full_name>Brandon Webb</investigator_full_name>
    <investigator_title>Director, Transplant Infectious Diseases</investigator_title>
  </responsible_party>
  <keyword>SARS-Co-V-2</keyword>
  <keyword>Hydroxychloroquine</keyword>
  <keyword>Azithromycin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>In order to protect patient privacy and comply with relevant regulations, identified data are unavailable. Requests for deidentified data from qualified researchers with appropriate ethics board approvals and relevant data use agreements will be processed by the Intermountain Office of Research, officeofresearch@imail.org.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

